Sign in

You're signed outSign in or to get full access.

Robertson H. Gilliland

Director at ADIAL PHARMACEUTICALS
Board

About Robertson H. Gilliland

Independent director since September 2014 (age 45) with an MBA from the University of Michigan’s Ross School of Business; chairs Adial’s Nominating & Corporate Governance Committee and is considered independent under Nasdaq rules . Background includes independent consulting to family offices since 2020, Principal & CFO at Keller Enterprises (2013–2020), and earlier Director at Brunswick Group focused on strategic communications and investor relations for major M&A transactions .

Past Roles

OrganizationRoleTenureCommittees/Impact
Keller Enterprises, LLCPrincipal & Chief Financial OfficerJul 2013–Apr 2020Oversaw family office investing; sourced, vetted, managed private direct investments; led strategic initiatives
Independent consultant (family offices)Investment strategy & governance advisorSince May 2020Focus on investment strategy formulation and governance
Brunswick GroupDirector (Strategic communications & IR)Pre-2011Advised on major M&A (Pfizer–Wyeth, Celgene–Pharmion, Mylan–Merck KGaA Generic); worked on 35+ multi‑billion transactions

External Roles

OrganizationRoleTenureNotes
No other public company directorships disclosed for Gilliland

Board Governance

  • Independence: Board determined Gilliland is “independent” under SEC/Nasdaq rules .
  • Committee assignments: Chair, Nominating & Corporate Governance; Member, Compensation Committee; not on Audit Committee .
  • Anticipated committee change: Proxy notes anticipated appointment to Compensation Committee immediately after 2025 annual meeting (now reflected in current committee table) .
  • Board leadership: Separate Chairman/Lead Independent Director (Kevin Schuyler); Gilliland supports governance via Nominating & Governance leadership .
  • Attendance: In FY2024, board held 6 meetings; each incumbent director (including Gilliland) attended no less than 75% of Board and committee meetings; Nominating & Governance met once . In FY2023, board held 12 meetings; each incumbent director attended ≥75%; Nominating & Governance met once .

Fixed Compensation

Non‑employee director pay (cash fees and option award value):

MetricFY 2023FY 2024
Fees Earned or Paid in Cash ($)$41,000 $44,000
Option Awards ($)$12,219 $13,628
Total ($)$53,219 $57,628

Director cash retainer schedule (company policy):

Role2023 Schedule ($)2024 Schedule ($)
Board Chair31,200 31,200
Board Member24,000 30,000
Audit Chair / Member16,000 / 8,000 16,000 / 8,000
Compensation Chair / Member11,000 / 6,000 11,000 / 6,000
Nominating & Gov Chair / Member8,000 / 4,000 8,000 / 4,000

Performance Compensation

Time‑vested option grants to directors (no performance metrics attached):

Grant YearGrant DateOptions (#)Exercise PriceVestingFair Value ($)
2023May 23, 202312,000 $7.50 36 months, monthly Included in $12,219 director option value
2024Mar 25, 202412,000 $1.35 36 months, monthly Included in $13,628 director option value
  • Options outstanding (non‑employee directors, Dec 31, 2024): Gilliland 19,823 .
  • Plan constraint: No option is exercisable later than 10 years after grant under the Equity Incentive Plan .

Other Directorships & Interlocks

CompanyRoleInterlocks/RelationshipsNotes
No external public company board roles disclosed for Gilliland; no interlocks noted .

Expertise & Qualifications

  • Finance and governance: Family office CFO and principal; investment strategy; private direct investing .
  • Capital markets & M&A: Strategic communications and IR on large M&A transactions at Brunswick Group .
  • Education: MBA (with honors), University of Michigan Ross School of Business .

Equity Ownership

As-of DateShares Beneficially Owned% of OutstandingNotes
Jun 4, 2025 (record date)16,490 <1% Includes options to purchase 16,490 shares exercisable within ~60 days; total option grants referenced elsewhere as 19,823 vs 47,823 in footnote, indicating doc inconsistency .
  • Anti‑hedging/anti‑pledging: Company Trading Policy prohibits hedging and pledging by directors/officers .
  • Clawback: Company has a clawback policy for incentive‑based compensation in the event of an Accounting Restatement .

Governance Assessment

  • Strengths: Independent status; chairing Nominating & Corporate Governance enhances board effectiveness in director selection, evaluations, and governance policy oversight . Attendance met ≥75% threshold; active committee participation . Anti‑hedging/pledging policy and clawback framework support alignment and accountability .
  • Compensation and alignment: Mix shifted toward higher cash retainer in 2024 (Board member fee $30,000 vs $24,000 in 2023), while equity remains time‑vested options without performance metrics; beneficial ownership is modest (<1%), limiting “skin‑in‑the‑game” but consistent with small-cap director norms .
  • Conflicts/related parties: No Gilliland‑specific related‑party transactions disclosed; related‑party engagements in the proxy pertain to other directors (e.g., Tony Goodman/Keswick/Orbytel) .
  • Net view: Governance role and independence are positives; absence of performance‑conditioned equity for directors and low ownership are neutral; no red flags specific to Gilliland identified in filings .

Note on insider trades: Attempted to retrieve Form 4 transactions using the insider‑trades skill for “Gilliland” at ADIL from 2024‑01‑01 to 2025‑11‑19, but the data source returned an authorization error; no Form 4 details were available via the tool at this time [tool error].